Lumera's Proprietary Protein Array Technology Featured in Nature Magazine Publication
December 14 2006 - 1:45PM
Business Wire
Lumera Corporation (NASDAQ:LMRA), an emerging leader in the field
of nanotechnology, was pleased to direct its various constituencies
today to the recent publication by Nature magazine of an article on
the subject of the growing capacity and need for protein arrays.
Lumera was one of the companies interviewed for the article which
was published in the December 14 issue of Nature magazine. The
well-known science magazine interviewed Dr. Tim Londergan, director
of the Lumera�s Bioscience Business Unit, and Ron Dudek, product
group manager, who discussed the field and Lumera�s ability to
offer higher protein array throughputs with its ProteomicProcessor�
over other available instruments. A link to a PDF file of the
article can be found at
http://www.nature.com/nature/journal/v444/n7121/index.html. Nature
is a weekly international journal publishing highly regarded
peer-reviewed research in all fields of science and technology and
provides authoritative, insightful news and coming trends affecting
science, scientists and the wider public. Tom Mino, President and
Chief Executive Officer of Lumera, said, �We see growing interest
in the scientific and research communities concerning Lumera�s
proprietary technology and we�re gratified to have a publication of
Nature�s caliber take notice. We are scheduled to showcase the
ProteomicProcessor� at a major protein conference in January and
look forward to the response from potential customers.� About
Lumera Lumera is a leader in the emerging field of nanotechnology.
The company designs proprietary molecular structures and polymer
compounds for the bioscience and communications/computing
industries, both of which represent large market opportunities. The
company also has developed proprietary processes for fabricating
such devices. For more information, please visit www.lumera.com.
Certain statements contained in this release are forward-looking
statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from
those projected in the company's forward-looking statements include
the following: market acceptance of our technologies and products;
our ability to obtain financing; our financial and technical
resources relative to those of our competitors; our ability to keep
up with rapid technological change; government regulation of our
technologies; our ability to enforce our intellectual property
rights and protect our proprietary technologies; the ability to
obtain additional contract awards and to develop partnership
opportunities; the timing of commercial product launches; the
ability to achieve key technical milestones in key products; and
other risk factors identified from time to time in the company's
SEC reports, including its Annual Report on Form 10-K, and its
Quarterly Reports on Form 10-Q.
Lumera (NASDAQ:LMRA)
Historical Stock Chart
From May 2024 to Jun 2024
Lumera (NASDAQ:LMRA)
Historical Stock Chart
From Jun 2023 to Jun 2024